The role of generic medicines has been to provide essential medicines that are both high quality and affordable throughout the EU. They have enabled increased access to medicines for patients and provided significant savings for EU healthcare systems.
The role of generic medicines in Europe
Home/Reports
|
Posted 11/06/2010
0
Post your comment
![picture41 picture41](/var/gabi/storage/images/media/images/picture41/4658-1-eng-GB/picture41_large.jpg)
In order to deliver the full benefits of generic medicines, greater importance must be placed on increasing volume rather than focusing simply on price. Reducing the price of generic medicines in low volume markets can affect the sector’s sustainability. In these countries the cost of maintaining the essential infrastructure related to registration costs, pharmacovigilance and other legal requirements will not be covered by the revenues generated.
Although generic medicines now fulfil over 50% of the demand for medicines in Europe, they still only represent 18% of the total medicines bill. Indeed, significant price decreases on many molecules, arising from competition or enforced pricing policy changes, has worked against growth in the generics sector.
A further benefit of generic medicines arises from continual provision of products many years after patent expiry. Whereas originators often exit the market invariably due to low volume demand, it is often the generic medicine that remains, meeting the needs of patients for whom there may be no other suitable alternative for their condition.
The generic medicines industry in Europe consists of more than 700 companies directly employing around 150,000 people and indirectly many more. The sector therefore represents significant economic value within the community.
Encouraging both competition between generic manufacturers, and the generic sector as a whole, will not only ensure lower costs for patients but also drive product improvements, distribution efficiencies and improved access to medicines.
(see also The rising cost of health care in Europe, Challenges facing generic manufacturers in Europe and Opportunities arising from increased use of generics)
Reference:
Alan Sheppard. Generic Medicines: Essential contributors to the long-term health of society. IMS Health Sector Sustainability Challenges in Europe. March 2010.
Policies & Legislation
China’s NMPA expands global ties with Netherlands and Indonesia
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Challenges and solutions in addressing the development void for oncology biosimilars
![150 AA010692 150 AA010692](/var/gabi/storage/images/media/images/150-aa0106922/21852-1-eng-GB/150-AA010692_large.jpg)
Home/Reports Posted 13/08/2024
Role of biologicals and biosimilars in cancer treatment amidst rising cases
![Cancer Cell V13I20 Cancer Cell V13I20](/var/gabi/storage/images/media/images/cancer-cell-v13i20/19527-1-eng-GB/Cancer-Cell-V13I20_large.jpg)
Home/Reports Posted 06/08/2024
FDA plans to standardize biosimilar approvals and boost access in FY 2025
![22 AA010963 22 AA010963](/var/gabi/storage/images/media/images/22-aa010963/36186-1-eng-GB/22-AA010963_large.jpg)
Home/Reports Posted 30/07/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment